ConductScience.org, home

Paper30282950

Regional Absorption of Fimasartan in the Gastrointestinal Tract by an Improved in situ Absorption Method in Rats.

Kim TH and 10 others. Pharmaceutics, 2018. Cited by 5 papers, by iCite.

Cite this record

ConductScience Library. Regional Absorption of Fimasartan in the Gastrointestinal Tract by an Improved in situ Absorption Method in Rats. Papers, record 30282950. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30282950

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Regional Absorption of Fimasartan in the Gastrointestinal Tract by an Improved in situ Absorption Method in Rats.
PubMed
Journal
Pharmaceutics
PubMed
Year
2018
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
5
iCite
Relative citation ratio, by iCite
0.33
iCite
Revised in PubMed
2020-10-01
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kim THTae Hwan
2Paik SHSoo Heui
3Chi YHYong Ha
4Bulitta JBJürgen B
5Lee DYDa Young
6Lim JYJun Young
7Chung SESeung Eun
8Song CHChang Ho
9Jeong HMHyeon Myeong
10Shin SSoyounghttps://orcid.org/0000-0001-8328-1087
11Shin BSBeom Soohttps://orcid.org/0000-0002-6706-5445

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
2018R1A2B6004928National Research Foundation of KoreaPubMed
16173MFDS542 in 2018Ministry of Food and Drug SafetyPubMed

Source PubMed

Download CSV of grants

References23

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
111274897Current methodologies used for evaluation of intestinal permeability and absorption.J Pharmacol Toxicol Methods2000https://conductscience.org/library/papers/11274897PubMed
211480535Evaluation of a single-pass intestinal-perfusion method in rat for the prediction of absorption in man.J Pharm Pharmacol2001https://conductscience.org/library/papers/11480535PubMed
41366578Solid phase membrane mimetics: immobilized artificial membranes.Enzyme Microb Technol1990https://conductscience.org/library/papers/1366578PubMed
617727800Predicting human intestinal permeability using single-pass intestinal perfusion in rat.J Pharm Pharm Sci2007https://conductscience.org/library/papers/17727800PubMed
721268050Simultaneous determination of fimasartan, a novel antihypertensive agent, and its active metabolite in rat plasma by liquid chromatography-tandem mass spectrometry.Biomed Chromatogr2011https://conductscience.org/library/papers/21268050PubMed
822264484Synthesis and antihypertensive activity of pyrimidin-4(3H)-one derivatives as losartan analogue for new angiotensin II receptor type 1 (AT1) antagonists.Bioorg Med Chem Lett2012https://conductscience.org/library/papers/22264484PubMed
922381711
Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.
Clin Ther2012https://conductscience.org/library/papers/22381711PubMed
1023811571Pharmacological characterization of BR-A-657, a highly potent nonpeptide angiotensin II receptor antagonist.Biol Pharm Bull2013https://conductscience.org/library/papers/23811571PubMed
1124206063Human in vivo regional intestinal permeability: importance for pharmaceutical drug development.Mol Pharm2014https://conductscience.org/library/papers/24206063PubMed
1224644298Quantitative determination of absorption and first-pass metabolism of apicidin, a potent histone deacetylase inhibitor.Drug Metab Dispos2014https://conductscience.org/library/papers/24644298PubMed
132470075The Madin Darby canine kidney (MDCK) epithelial cell monolayer as a model cellular transport barrier.Pharm Res1989https://conductscience.org/library/papers/2470075PubMed
1424786684Pharmacokinetics and metabolite profiling of fimasartan, a novel antihypertensive agent, in rats.Xenobiotica2014https://conductscience.org/library/papers/24786684PubMed
1525990964Population Pharmacokinetic Modeling of the Enterohepatic Recirculation of Fimasartan in Rats, Dogs, and Humans.AAPS J2015https://conductscience.org/library/papers/25990964PubMed
1626272450Absolute bioavailability and pharmacokinetics of the angiotensin II receptor antagonist fimasartan in healthy subjects.J Clin Pharmacol2016https://conductscience.org/library/papers/26272450PubMed
1726895020Predicting Drug Extraction in the Human Gut Wall: Assessing Contributions from Drug Metabolizing Enzymes and Transporter Proteins using Preclinical Models.Clin Pharmacokinet2016https://conductscience.org/library/papers/26895020PubMed
1827768097Materials and methods for delivery of biological drugs.Nat Chem2016https://conductscience.org/library/papers/27768097PubMed
1928920690Regional Intestinal Permeability in Rats: A Comparison of Methods.Mol Pharm2017https://conductscience.org/library/papers/28920690PubMed
204692832Glucose transport in isolated brush border membrane from rat small intestine.J Biol Chem1973https://conductscience.org/library/papers/4692832PubMed
217266016Predicted absorption rates with simultaneous bulk fluid flow in the intestinal tract.J Theor Biol1981https://conductscience.org/library/papers/7266016PubMed
228527686Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals.Biopharm Drug Dispos1995https://conductscience.org/library/papers/8527686PubMed

See all 23 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.

PMIDTitleJournalYearIn PapersSource
33440126Role of MALDI-MSI in combination with 3D tissue models for early stage efficacy and safety testing of drugs and toxicants.Expert Rev Proteomics2020https://conductscience.org/library/papers/33440126PubMed
33050089Hyaluronic Acid in the Intestinal Tract: Influence of Structure, Rheology, and Mucoadhesion on the Intestinal Uptake in Rats.Biomolecules2020https://conductscience.org/library/papers/33050089PubMed
31938935Development of a Population Pharmacokinetics-Based in vitro-in vivo Correlation Model for Drugs with Site-Dependent Absorption: the Acyclovir Case Study.AAPS J2020https://conductscience.org/library/papers/31938935PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/30282950

GET https://conductscience.org/api/papers/v1/30282950/references?page=2